Scienture Holdings Reports FY25 Financial Results, Provides Business Update
ByAinvest
Monday, Mar 30, 2026 11:20 am ET1min read
SCNX--
Scienture Holdings reported its year-end 2025 financial results and provided a business update. The company operates through Scienture, LLC, a branded specialty pharmaceutical company, and Integra Pharma Solutions, LLC, a pharmaceutical supplier. Scienture's assets in development include SCN-102 (cardiovascular), SCN-104 (CNS-Pain), SCN-105 (CNS), SCN-106 (cardiovascular), and SCN-107 (Pain). The company aims to provide value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the United States.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue



Comments
No comments yet